Early Assets Excite At Novartis R&D Day
430 drug discovery projects trimmed to 325
NIBR chief Jay Bradner tells Scrip that the Swiss major's focus is on developing first in class therapies rather than 'fast-follower' research seen across the biopharma sector.
You may also be interested in...
Cadila Healthcare has entered the immuno-oncology race by inking a licensing agreement with US-based XOMA for a drug candidate that combines the Indian firm's interleukin-2 with the latter’s novel anti-IL-2 monoclonal antibody
Any lingering hopes Novartis had that fevipiprant could become a blockbuster have disappeared and the Swiss major has ended development of the asthma drug after two more trials failed, this time for severe disease.
The company Novartis is buying for $9.7bn is largely unrecognizable from the one Clive Meanwell started in 1996, grew into a multi-product hospital specialist and began to sunset in 2015 with the loss of Angiomax.